Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research InstituteJohn D. Hainsworth, F. Anthony Greco, Samuel Raby et al.|Journal of Clinical Oncology|2012Cited by 373
Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients (pts) with carcinoma of unknown primary site (CUP): Results of a prospective Sarah Cannon Research Institute (SCRI) trial.Frank A. Greco, John D. Hainsworth, Mark S. Rubin et al.|Journal of Clinical Oncology|2012Cited by 4